What are needs unmet by the current treatment patterns for patients uncontrolled gout?

Unmet needs in uncontrolled gout include ongoing flares and tophi formation despite standard therapy, restricted treatment options for patients with kidney or heart disease, drug safety concerns, and barriers to optimal care management.

Abstract

Patients with uncontrolled gout face several challenges that current treatment patterns do not address. Studies report that patients with refractory or treatment‐failure gout continue to experience frequent flares, tophaceous deposits, and high healthcare use despite conventional urate‐lowering therapy. One set of papers finds that 15–32% of patients remain difficult to treat even with aggressive management.

Unmet needs include:

1. Persistent disease activity—with recurrent flares and tophi formation—despite standard therapy.
2. Limited safe and effective options for patients with comorbid conditions (notably chronic kidney and cardiovascular disease), given dosing constraints and increased adverse effects.
3. Safety and tolerability issues, such as immunogenicity and infusion reactions with agents like pegloticase.
4. Barriers to optimal management arising from poor treatment adherence, inadequate patient–provider communication, and clinical inertia.

These studies indicate that existing treatment strategies often fall short for patients with uncontrolled gout, leaving a need for approaches that directly address these clinical and management gaps.

Methods

We analyzed 40 sources from an initial pool of 997, using 8 screening criteria. Each paper was reviewed for 5 key aspects that mattered most to the research question.

Results

Characteristics of Included Studies

Across 40 studies, the following patterns were identified in patient populations, treatment contexts, and unmet needs in gout care:

Patient Populations Studied:

• 21 studies included uncontrolled, refractory, or treatment-failure gout.
• 22 studies included gout with comorbidities (such as chronic kidney disease, cardiovascular disease).
• 9 studies included chronic or complicated gout (not specifically uncontrolled).

Treatment Contexts:

• 31 studies discussed urate-lowering therapy, including allopurinol, febuxostat, uricosurics, and pegloticase.
• 7 studies discussed non-urate-lowering pharmacologic treatments (nonsteroidal anti-inflammatory drugs, colchicine, corticosteroids, interleukin-1 blockers, etc.).

Key Findings Related to Unmet Needs:

• 18 studies identified poor adherence or suboptimal management as an unmet need.
• 13 studies highlighted the need for new or alternative therapies, especially for refractory or comorbid cases.

Thematic Analysis

Refractory and Difficult-to-Treat Gout

• A subset of patients with refractory or treatment-failure gout experience persistent symptoms, frequent flares, and tophaceous deposits despite aggressive therapy.
• These patients often have multiple comorbidities, particularly chronic kidney disease.

Treatment Limitations in Patients with Comorbidities

• Comorbidities, especially chronic kidney disease and cardiovascular disease, are major barriers to effective gout management.

Safety and Tolerability Concerns with Current Therapies

• Safety and tolerability issues are prominent, particularly in patients with comorbidities.

Adherence Challenges and Clinical Management Gaps

• Adherence to urate-lowering therapy and guideline-recommended care is consistently suboptimal, with both patient and provider factors contributing.